No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
www.santen.comNo one on the platform currently holds 4536.T.
No tracked institution reports a position in 4536.T as of their last filing.
No one on the platform has traded 4536.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.3% | — | — | — | ||
| Rev. Growth % | -2.8% | 3.2% | ||||
| Profit Margin % | 12.8% | 7.7% | 9.2% | |||
| Free Cash Flow Margin % | 12.6% | 13.9% | 13.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $304.0B | +4.7% | $119.10 | $100.50–$126.35 | — | 8 |
| 2028 | $314.4B | +3.4% | $131.15 | $100.57–$163.58 | — | 8 |
| 2029 | $326.8B | +3.9% | $145.40 | $108.04–$169.13 | — | 6 |
| 2030 | $350.2B | +7.2% | $170.29 | $157.92–$186.03 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | $21.27 | $22.38 | +5.2% |
| 2026-05-12 | $30.79 | $47.88 | +55.5% |
| 2026-02-05 | $29.29 | $24.40 | -16.7% |
| 2025-11-06 | $20.89 | $24.44 | +17.0% |
| 2025-08-07 | $23.90 | $17.32 | -27.5% |
| 2025-05-13 | $17.30 | $25.77 | +49.0% |
| 2025-02-06 | $24.24 | $25.33 | +4.5% |
| 2024-11-07 | $21.69 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 4536.TSanten Pharmaceutical Co., Ltd. | $1742.00 | -0.06% | $560.4B | — |
| 2784.TAlfresa Holdings Corporation | $2336.50 | -0.19% | $409.9B | — |
| 3349.TCOSMOS Pharmaceutical Corporation | $6608.00 | -1.34% | $523.7B | — |
| 3549.TKusuri No Aoki Holdings Co., Ltd. | $4057.00 | -0.64% | $385.3B | — |
| 4530.THisamitsu Pharmaceutical Co., Inc. |
| $23.29 |
| +7.4% |
| $6040.00 |
| +0.00% |
| $425.2B |
| — |
| 4547.TKissei Pharmaceutical Co., Ltd. | $4015.00 | -0.12% | $166.4B | — |
| 7459.TMediPal Holdings Corporation | $2923.50 | -0.51% | $598.4B | — |
Source: Financial Modeling Prep · peers by sector/industry